NAUT

Goldman Sachs analyst Matthew Sykes maintained a Hold rating on Nautilus Biotechnolgy (NAUT – Research Report) today and set a price target of $2.00. The company's shares closed last Wednesday at $2.89, close to its 52-week low of $2.53. According to TipRanks.com, Sykes has 0 stars on 0-5 stars ranking scale with an average return of -13.4% and a 43.2% success rate. Sykes covers the Healthcare sector, focusing on stocks such as Singular Genomics Systems, Sema4 Holdings, and Mettler-Toledo. Nautilus Biotechnolgy has an analyst consensus of Moderate Buy, with a price target consensus of $6.33, implying an 119.8% upside from current levels.
https://www.tipranks.com/news/blurbs/nautilus-biotechnolgy-naut-gets-a-hold-rating-from-goldman-sachs?utm_source=advfn.com&utm_medium=referral